Nisha Pandey

Health and Me

Could A Daily Pill Help Prevent Breast Cancer Recurrence? Roche's Promising Experimental Drug Awaits FDA Approval

An experimental daily pill developed by Swiss healthcare company F Hoffmann-La <span>Roche</span> AG has sparked hope for a new treatment option for people with early-stage <span><a href="https://www.healthandme.com/health/breast-cancer">breast cancer</a></span>. The drug, giredestrant, reduced the risk of invasive disease recurrence or death by at least 30% compared to standard hormone therapy, according to findings from its Phase 3 trial.

The <span>US Food and Drug Administration</span> (<span>FDA</span>) is expected to share its drug approval verdict by November 30, 2026.

Giredestrant is an experimental once-daily pill designed to block and degrade oestrogen receptors, which can contribute to breast cancer risk. 

It is being studied in oestrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype that accounts for the majority of breast cancer diagnoses.

<h2>Breast Cancer Drug Giredestrant’s Trial</h2>

Also read: <a href="https://www.healthandme.com/health-wellness/breast-cancer-awareness-month-advancing-a-risk-informed-and-equitable-approach-to-breast-cancer-screening-in-india-article-156379530" data-type="tilCustomLink">Breast Cancer Awareness Month: Advancing A Risk-Informed and Equitable Approach to Breast Cancer Screening in India</a>

The Phase 3 <span>lidERA</span> trial, involving 4,100 people with early-stage ER-positive, HER2-negative <a href="https://www.healthandme.com/health/breast-cancer" data-type="tilCustomLink">breast cancer</a>, compared giredestrant to standard endocrine therapy.

The results showed that giredestrant reduced the risk of disease recurrence or death by 30% relative to standard endocrine therapy.

At three years, 92.4% of participants receiving giredestrant were alive and free of invasive disease, compared to 89.6% of those receiving standard treatment.

Even though the trial met its primary goal, overall survival data was still immature at the time of analysis. Hence, the findings depict an improvement in invasive disease-free survival, not proof that the drug helps people live longer.

Giredestrant was generally well tolerated in the trial. Treatment was discontinued because of adverse events in 5.3% of participants receiving the drug, compared to 8.2% receiving standard endocrine therapy.

<h2>Latest Developments In October 2026</h2>

Also read: <a href="https://www.healthandme.com/health-wellness/breast-cancer-awareness-day-experts-explain-most-overlooked-breast-changes-that-can-delay-diagnosis-in-men-article-156364460" data-type="tilCustomLink">Breast Cancer Awareness Day: Experts Explain Most Overlooked Breast Changes That Can Delay Diagnosis In Men</a>

On October 19, Roche announced that it would present new giredestrant data at the 2026 ESMO Annual Meeting, scheduled for October 23 to 27 in Madrid.

The presentation includes outcomes reported by patients from the lidERA trial. According to Roche, these findings suggest that the promising results in reducing disease recurrence seen with giredestrant was achieved without compromising tolerability or quality of life of the patients.

The company will also present biomarker findings from the evERA trial, which was based on giredestrant combined with everolimus in advanced breast cancer. These are separate settings from using giredestrant alone after surgery for early-stage disease.

Breast Cancer Symptoms, Screening & Treatment | Breast Cancer Awareness Month

Earlier in October, detailed results from the Phase 3 evERA trial were published in <em>The <span rel="noindex">New England Journal of Medicine</span></em>. 

In people with advanced ER-positive, HER2-negative breast cancer, giredestrant combined with everolimus reduced the risk of disease progression or death by 44%.

With 62%, the combination showed even results among participants whose tumours had an ESR1 mutation, compared to standard endocrine therapy combined with everolimus. The FDA has set December 18, 2026, to announce its decision for this combination in certain patients with advanced breast <a href="https://www.healthandme.com/health-news/jeana-keoughs-cancer-battle-why-the-rhoc-star-is-struggling-to-recover-after-tongue-cancer-treatment-article-156382561" data-type="tilCustomLink">cancer</a>.

The FDA accepted Roche's application for giredestrant as an adjuvant treatment for adults with stage I to III ER-positive, HER2-negative breast cancer under priority review. The decision will be made on November 30, 2026. 

If approved, giredestrant’s use will depend on the overall clinical guidance and patient's individual circumstances. According to <em>Bloomberg</em>, the drug is expected to generate up to $15 billion in revenue.

Health Conditions A-Z

health

could-a-daily-pill-help-prevent-breast-cancer-recurrence-roches-promising-experimental-drug-awaits-fda-approval

roche

breast cancer

roche breast cancer pill

lidera

us food and drug administration

new england journal of medicine

FSSAI Questions Complan's ‘2X Faster Growth’ Claim; Flags Nestlé, Abbott And Nutricia's Infant Formula

worlds-first-human-case-of-shamonda-virus-reported-in-france-patient-dies-should-people-be-worried

World’s First Human Case Of Shamonda Virus Reported In France; Patient Dies: Should People Be Worried?

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

An experimental daily pill developed by Swiss healthcare company F Hoffmann-La Roche AG has sparked hope for a new treatment option for people with early-stage breast cancer. The drug, giredestrant, reduced the risk of invasive disease recurrence or death by at least 30% compared to standard hormone therapy, according to findings from its Phase 3 trial. The US Food and Drug Administration (FDA) is expected to share its drug approval verdict by November 30, 2026.Giredestrant is an experimental once-daily pill designed to block and degrade oestrogen receptors, which can contribute to breast cancer risk. It is being studied in oestrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype that accounts for the majority of breast cancer diagnoses. Breast Cancer Drug Giredestrant’s Trial Also read: Breast Cancer Awareness Month: Advancing A Risk-Informed and Equitable Approach to Breast Cancer Screening in IndiaThe Phase 3 lidERA trial, involving 4,100 people with early-stage ER-positive, HER2-negative breast cancer, compared giredestrant to standard endocrine therapy.The results showed that giredestrant reduced the risk of disease recurrence or death by 30% relative to standard endocrine therapy. At three years, 92.4% of participants receiving giredestrant were alive and free of invasive disease, compared to 89.6% of those receiving standard treatment.Even though the trial met its primary goal, overall survival data was still immature at the time of analysis. Hence, the findings depict an improvement in invasive disease-free survival, not proof that the drug helps people live longer.Giredestrant was generally well tolerated in the trial. Treatment was discontinued because of adverse events in 5.3% of participants receiving the drug, compared to 8.2% receiving standard endocrine therapy. Latest Developments In October 2026Also read: Breast Cancer Awareness Day: Experts Explain Most Overlooked Breast Changes That Can Delay Diagnosis In MenOn October 19, Roche announced that it would present new giredestrant data at the 2026 ESMO Annual Meeting, scheduled for October 23 to 27 in Madrid.The presentation includes outcomes reported by patients from the lidERA trial. According to Roche, these findings suggest that the promising results in reducing disease recurrence seen with giredestrant was achieved without compromising tolerability or quality of life of the patients.The company will also present biomarker findings from the evERA trial, which was based on giredestrant combined with everolimus in advanced breast cancer. These are separate settings from using giredestrant alone after surgery for early-stage disease.                   Earlier in October, detailed results from the Phase 3 evERA trial were published in The New England Journal of Medicine. In people with advanced ER-positive, HER2-negative breast cancer, giredestrant combined with everolimus reduced the risk of disease progression or death by 44%. With 62%, the combination showed even results among participants whose tumours had an ESR1 mutation, compared to standard endocrine therapy combined with everolimus. The FDA has set December 18, 2026, to announce its decision for this combination in certain patients with advanced breast cancer. The FDA accepted Roche's application for giredestrant as an adjuvant treatment for adults with stage I to III ER-positive, HER2-negative breast cancer under priority review. The decision will be made on November 30, 2026. If approved, giredestrant’s use will depend on the overall clinical guidance and patient's individual circumstances. According to Bloomberg, the drug is expected to generate up to $15 billion in revenue.

could a daily pill help prevent breast cancer recurrence? roche's promising experimental drug awaits fda approval

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Could A Daily Pill Help Prevent Breast Cancer Recurrence? Roche's Promising Experimental Drug Awaits FDA Approval

World’s First Human Case Of Shamonda Virus Reported In France; Patient Dies: Should People Be Worried?

Jeana Keough’s Cancer Battle: Why The ‘RHOC’ Star Is Struggling To Recover After Tongue Cancer Treatment

Daily Vaping In The US Surged 230%; Nearly 50% Of Young Adult Daily Vapers Used High-Nicotine E-Cigarettes: Studies

Health Conditions A-Z

Could A Daily Pill Help Prevent Breast Cancer Recurrence? Roche's Promising Experimental Drug Awaits FDA Approval

FSSAI Questions Complan's ‘2X Faster Growth’ Claim; Flags Nestlé, Abbott And Nutricia's Infant Formula

World’s First Human Case Of Shamonda Virus Reported In France; Patient Dies: Should People Be Worried?